AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27879195
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of test to reference formulation
Trial: 16626571
Drug: Intracoronary PBSCs
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary PBSCs transplantation following G-CSF mobilization (300-600 microg/day for 5 days)
Trial: 16626571
Drug: Intracoronary PBSCs
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary PBSCs transplantation following G-CSF mobilization
Trial: 16626571
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (standard drug therapy and PCI)
Trial: 9753961
Drug: Fentanyl 0.1
RxNorm normalized name: fentanyl 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.1 mg 3 min prior to propofol
Trial: 9753961
Drug: Lidocaine 40
RxNorm normalized name: lidocaine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg added to 200 mg propofol
Trial: 9753961
Drug: Fentanyl 0.1
RxNorm normalized name: fentanyl 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.1 mg 3 min prior to propofol mixed with lidocaine 40 mg
Trial: 9753961
Drug: Injection via
RxNorm normalized name: vial,empty INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection via the forearm vein
Trial: 2497096
Drug: Oxaprozin 600
RxNorm normalized name: oxaprozin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaprozin 600 mg/day
Trial: 30585904
Drug: Daily caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily caffeine intake
Trial: 15256687
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of whey protein (17.5 g), amino acids (4.9 g), and carbohydrates (77.4 g) (PAAC)
Trial: 15256687
Drug: Isoenergetic carbohydrates
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic carbohydrates (100 g) (CON)
Trial: 9137476
Drug: D‐galactose (1.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐galactose (1.9 g/kg BW and day)
Trial: 7964541
Drug: Alpha-galactosidase solution
RxNorm normalized name: ALPHA-GALACTOSIDASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-galactosidase solution (8 drops)
Trial: 3058656
Drug: Prostatic bed
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostatic bed irradiation only (6500 cGy at 180‐200 cGy per treatment)
Trial: 3058656
Drug: Pelvic node
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic node irradiation to 4500 cGy with a boost of 2000 cGy to the prostatic bed (total dose 6500 cGy)
Trial: 25611899
Drug: Nonpegylated doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpegylated doxorubicin citrate (60 mg/m) and carboplatin (AUC 5) every 3 weeks for 6 to 9 cycles
Trial: 21516059
Drug: Levothyroxine sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine sodium soft capsule formulation (Tirosint)
Trial: 21516059
Drug: 50-, 100-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-, 100-, and 150-μg test capsules strengths dosed at 600 μg
Trial: 21516059
Drug: New capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New capsule formulation following the new potency guideline (±5%)
Trial: 16601647
Drug: Paroxetine (10-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10-50 mg/day)
Trial: 1305891
Drug: Interferon alfa‐n3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐n3 (Alferon N Injection)
Trial: 2867653
Drug: etintidine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etintidine 300 mg
Trial: 2867653
Drug: etintidine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etintidine 600 mg
Trial: 25209306
Drug: Living in
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living in a couple with a non-drug user
Trial: 25209306
Drug: Living in
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living in a couple with a drug user
Trial: 19317607
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg weekly
Trial: 21989542
Drug: Etanercept (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (both doses)
Trial: 20979784
Drug: rhPTH (1‐34)
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH (1‐34) 20 µg daily
Trial: 16093464
Drug: Alendronate after
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate after parathyroid hormone (1-84) therapy
Trial: 16093464
Drug: Placebo after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo after parathyroid hormone (1-84) therapy
Trial: 12501881
Drug: Sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg administered on the last day of the OC regimen
Trial: 12501881
Drug: Norethindrone 1
RxNorm normalized name: norethindrone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone 1 mg/ethinyl estradiol 0.035 mg (NE/EE)
Trial: 1645384
Drug: SDZ 89‐104,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ 89‐104, 2 mg/kg
Trial: 1645384
Drug: SDZ 89‐109,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ 89‐109, 2 mg/kg
Trial: 1645384
Drug: SDZ 89‐104,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ 89‐104, 0.5 mg/kg
Trial: 1645384
Drug: SDZ 89‐109,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDZ 89‐109, 0.5 mg/kg
Trial: 1645384
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum levels (2 mg/kg)
Trial: 28738008
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yunnan Baiyao (15 mg/kg)
Trial: 25941765
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (300 mg per day for 20 days)
Trial: 25941765
Drug: Placebo supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplementation (300 mg per day for 20 days)
Trial: 24885672
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine (Salbutamol, Formoterol, Salmeterol/fluticasone)
Trial: 24885672
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) treatments (Bufei granule, Bu‐Fei Jian‐Pi granule, Bu‐Fei Yi‐Shen granule, Yi‐Qi Zi‐Shen granule)
Trial: 24885672
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of conventional Western medicine and TCM treatments
Trial: 16923461
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose
Trial: 21685174
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose
Trial: 17445432
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (300 mg and 600 mg)
Trial: 14709457
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 10 mg.kg(‐1) bolus before surgery plus a 1 mg.kg(‐1).hr(‐1) infusion until wound closure (Group TA)
Trial: 9737091
Drug: meloxicam 7.5
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 7.5 mg/d for 6 days
Trial: 9737091
Drug: indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: indomethacin 25 mg tid for 2 days and 25 mg on the 3rd day
Trial: 7995320
Drug: Nonfiltered 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonfiltered 0 mg nicotine cigarette
Trial: 7995320
Drug: Low (0.27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low (0.27 mg) nicotine cigarette
Trial: 7995320
Drug: High (2.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High (2.16 mg) nicotine cigarette
Trial: 2843029
Drug: Oat and
RxNorm normalized name: Oat and wheat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat and bean products as dietary supplements
Trial: 29966645
Drug: Interactive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive group treatment (13 weekly sessions, 1.5 hours each) with structured and facilitated group interactions
Trial: 29966645
Drug: Noninteractive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninteractive treatment (13 traditional classroom sessions with brief supplemental individual sessions)
Trial: 26867200
Drug: DHA as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA as part of a multinutrient supplement (including Gingko biloba, phosphatidylserine, vitamins B₉ and B₁₂)
Trial: 18702660
Drug: EC‐MPS (1080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐MPS (1080 mg bid)
Trial: 18702660
Drug: MMF (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (1500 mg bid)
Trial: 16880774
Drug: GHB (2‐18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (2‐18 g/70 kg)
Trial: 16880774
Drug: Triazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.5 and 1 mg/70 kg)
Trial: 16880774
Drug: Pentobarbital (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital (200 and 400 mg/70 kg)
Trial: 8380634
Drug: Cisplatin (CDDP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Vindesine (VDS; 3 mg/m2 on days 1 and 8)
Trial: 8380634
Drug: Cisplatin (CDDP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP; 80 mg/m2 on day 1) plus Mitomycin C (MMC; 8 mg/m2 on days 1 and 8)
Trial: 30236087
Drug: Dacryocystorhinostomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacryocystorhinostomy with Silicone tubes and Ologen implants (Group B)
Trial: 15735611
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice 300 mL
Trial: 15735611
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice 1200 mL
Trial: 12824095
Drug: Ex‐warfarin users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex‐warfarin users
Trial: 8856481
Drug: LRB081 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRB081 10 mg
Trial: 8856481
Drug: LRB081 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRB081 40 mg
Trial: 8856481
Drug: LRB081 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LRB081 80 mg
Trial: 1732347
Drug: Urokinase (4,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urokinase (4,400 U/kg as an intravenous bolus infusion, then 4,400 U/kg per h over 12 h; n = 29)
Trial: 1732347
Drug: Alteplase (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (10 mg as an intravenous bolus infusion, then 90 mg over 2 h; n = 34)
Trial: 12416659
Drug: IBI/S (silybin-beta-cyclodextrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI/S (silybin-beta-cyclodextrin) 135 mg/d
Trial: 8595515
Drug: Double combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double combination therapy
Trial: 792404
Drug: Estolate suspension
RxNorm normalized name: meadowfoam estolide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estolate suspension
Trial: 792404
Drug: Ethyl succinate
RxNorm normalized name: Dimethyl succinate
DrugBank: Triethyl phosphate (DB03347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl succinate suspension
Trial: 28557589
Drug: Ophthalmic viscosurgical
RxNorm normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic viscosurgical device
Trial: 23352760
Drug: Morphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine treatment (10 μg/kg/h during the neonatal period)
Trial: 10398579
Drug: ThinPrep preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ThinPrep preparations
Trial: 22543884
Drug: Total radiation
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total radiation dose
Trial: 1854047
Drug: Etomidate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.5 mg.kg‐1)
Trial: 31701432
Drug: No recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No recall period (standard PROMIS administration)
Trial: 17906192
Drug: EGCG (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (300 mg/d for 2 days)
Trial: 16140426
Drug: 2 cans/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cans/day of a protein and energy dense oral nutrition supplement +/− n-3 fatty acids
Trial: 2138489
Drug: Doxacurium (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxacurium (initial dose of 25 micrograms kg‐1, with incremental doses of 5 micrograms kg‐1)
Trial: 2138489
Drug: Neostigmine (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.08 mg kg‐1)
Trial: 2138489
Drug: Edrophonium (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (1.0 mg kg‐1)
Trial: 30082073
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg daily
Trial: 16401736
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg daily
Trial: 24885673
Drug: Dader Method
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dader Method of pharmaceutical care
Trial: 21418281
Drug: Topical 3%
RxNorm normalized name: sulfur topical 3% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 3% diclofenac sodium plus hyaluronan (DFS) gel, twice daily for 12 weeks
Trial: 21418281
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% imiquimod (IMQ) cream, twice per week for 16 weeks
Trial: 21418281
Drug: Base cream
RxNorm normalized name: U-Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base cream (BC), twice daily for 12 weeks
Trial: 15643103
Drug: Gepirone ER
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone ER (20 mg/d titrated to 40 to 80 mg/d)
Trial: 12224305
Drug: Immunosuppressive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive agents and 99Tc-MDP
Trial: 10428516
Drug: Intracutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injections of 0.1 mL sterile water
Trial: 10428516
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of 0.5 mL sterile water
Trial: 1969982
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion at progressively increased concentrations
Trial: 17321923
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 10 mg of hyperbaric 1% lidocaine (L group, n=40)
Trial: 17321923
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with fentanyl 1 microg.kg‐1 IV and 1.0 mg.kg‐1 propofol (F/P group, n=40)
Trial: 15646652
Drug: Ferrous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous iron supplement (Ferall, a combination of ferrous fumarate with ascorbic acid, folic acid, and cyanocobalamin)
Trial: 3139571
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 250 mg mixed testosterone esters at 2-week intervals
Trial: 3139571
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate 120 mg bd
Trial: 3139571
Drug: Subcutaneous testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous testosterone pellets (6 x 100 mg)
Trial: 26214071
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with GBNs (13 g/day for three months)
Trial: 23356951
Drug: Virtual reality‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality‐based vocational training group (VRG) and therapist‐administered group (TAG)
Trial: 16958945
Drug: SSRI‐assisted BDZ‐reduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI‐assisted BDZ‐reduction group (10‐20 mg of paroxetine, n = 22)
Trial: 15534491
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine given daily for 4 days
Trial: 11464354
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg of intraarticular clonidine with subcutaneous saline
Trial: 11464354
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg of intraarticular neostigmine with subcutaneous saline
Trial: 11464354
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg of intraarticular clonidine and 500 microg of neostigmine with subcutaneous saline
Trial: 11464354
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg of intraarticular clonidine with 500 microg of subcutaneous neostigmine
Trial: 11464354
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg of intraarticular neostigmine with 150 microg of subcutaneous clonidine
Trial: 11464354
Drug: intraarticular and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarticular and subcutaneous isotonic saline
Trial: 7893580
Drug: Didanosine 100
RxNorm normalized name: didanosine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 100 mg
Trial: 3556193
Drug: Slow-release oxprenolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oxprenolol 160 mg
Trial: 3556193
Drug: Slow-release oxprenolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oxprenolol 320 mg
Trial: 3556193
Drug: Oros oxprenolol
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oros oxprenolol 10/170 mg
Trial: 24363363
Drug: Amoxicillin dissolved
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin dissolved in human milk at a concentration of 50 mg/mL
Trial: 24363363
Drug: Amoxicillin dissolved
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin dissolved in water at a concentration of 50 mg/mL
Trial: 20035226
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg kg(‐1)
Trial: 20035226
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg kg(‐1) + low-dose oral ketamine 2 mg kg(‐1)
Trial: 2707399
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (both groups)
Trial: 17642108
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose lithium chloride (0.72 mEq/kg/day)
Trial: 17642108
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose lithium chloride (0.5 mEq/kg/day)
Trial: 17642108
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose lithium chloride (0.24 mEq/kg/day)
Trial: 28526329
Drug: Sham intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham intervention consisting of weekly phone calls for 6 weeks.
Trial: 22554598
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg prasugrel
Trial: 21784373
Drug: Extended-release niacin/laropiprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin/laropiprant (1g niacin/20 mg laropiprant) for the first 4 weeks, then 2 tablets once daily thereafter